response. The other forms of impaired glucose homeostasis can be due to different genetic defects. destruction of the exocrine pancreas or malfunction of other endocrine organs. 1 In 1997 the number of people affected by diabetes mellitus was approximately 130 million worldwide. with an overwhelming preponderance of type 2 (> 90%). For mUltiple reasons. it is estimated that the total will reach 220 million by the year 2010. 2 The rise is not expected to be homogeneously distributed. For example. changes in lifestyle in 'recently modernized' parts of the world (e.g. Asian and African countl-ies) will probably result in disproportionately higher increases in diabetes. In contrast. the fraction of type I diabetes is expected to increase over time in developed countries where longer survival after diagnosis results from greater availability of sophisticated care. Relative to the Caucasian popUlation, the incidence of. and the genetic susceptibility to. diabetes and its complications, selectively target ethnic groups such as African-Americans. Hispanic-Americans and Native Americans. 3 -s Despite improvements in care, the life expectancy of victims of diabetes is at least 10 years shorter in the United States than that of the rest of the population. 3 Cardiovascular disease, end-stage renal disease and diabetic retinopathy are the major morbidity factors in diabetic people. s - 7 One-third of all type I diabetic individuals have one or more lethal or life-ruining complications that are directly attributable to the underlying diabetes.
The prevention of these and other complications has been improved by technologies that allow the accurate monitoring of blood sugar and/or more flexible administration of appropriate quantities of insulin (i.e. intensified therapy). The Diabetes Control and Complicatiqn Trial (DCCT) has examined the impact of glycaemic control on the early occurrence of microvascular. neuropathic and macrovascular complications 8 in type I diabetic patients. These studies demonstrated that intensive insulin therapy with tight glycaemic control could reduce but not completely eliminate the risk for development of some of the most devastating complications.
For the patient with type I diabetes. definitive treatment without resorting to the use of exogenous insulin can be achieved presently only with pancreas or islet cell transplantation. These means of restoring ~-cell mass can completely maintain essentially normal long-term glucose homeostasis. Apart from the shortage of donors that has limited all kinds of transplantation. however. the widespread use of pancreas transplantation has been precluded until recently by the imperfections of both organ and islet cell transplantation.
PANCREAS TR'ANSPLANTATION
The unresolved problems of pancreas transplantation that were identified from the beginning were both technical and immunological. The immunological category has been the most important. the least understood. and therefore, the most daunting. Rejection has not been the only immune barrier because even I"ecurrence of autoimmune diabetes occur/"eo in recipients of panCJ"eatic grafts 9 The fundamental ':Jbstacie co pancreas transplantation has been. and I"emains, the allolmmune I"esponse "Tloullted against genetically non-identlcai donor tISsue. The quality of immunosuppression has dictated which of the various operative procedures was :tdopted. Moreover", the Illorbidity and mortality inherent III chmllic ImmunosuppreSSion ~Ontlnues even coday :0 ,nfluence che selection of l-eClplents. ! '''~'I,''?n' I'espans" WitI' "Tad,atlon and dl'ugs.'! As expectec;, tlife ilst of compiicatlons from the: !-c<;ultlng loss or immune surveillance was a long one that could be diVided In two calegones: susceptibility to Infections and the development of de novo malignancies, ii! Jdditlorl, every potent Immunosuppressant has Its speCIfic tOXicity profile, Of the dozens of drugs that have been tested clinically, only three have been widely used fOI· continuous baselme therapy azathioprine l2 , cyclosponne 13 Jnd tacrollmus." Dose ranges are available for these immunosuppressants, but for each, and fOI-more recently Introduced ones (e.g, sirolimus ls and mycophenolate mofetil, MMF lb ), the appmpriate dose must be established by trial and error for evel-y transplant recipient. The dose ceilings are imposed acutely by drug toxicity, and the dose floors are revealed by breakthrough rejection. The complex limiting side-effects of the calcineurin inhibitors (cyclosporine and tacrolimus) are of specific interest here, since both cyclosporine and tacrolimus are diabetogenic, nephrotoxic and neurotoxic. Such qualities are not seen with the other T-cell-directed agent, sirolimus, which has its own distinctive panoply of dose-limiting side-effects. IS When given after transplantation, none of the foregoing drugs can reliably prevent post-transplant rejection when used alone. However, it was learned in 1962-63 that organ rejection could readily be reversed by adding large doses of prednisone to primary azathioprine treatment, and that the subsequent dose requirements of both azathioprine and prednisone (the 'double-drug cocktail') frequently declined. '7 In 1966, a short course of anti lymphoid globulin (ALG) was added to azathioprine and prednisone (the 'triple-drug cocktail'), with a substantial reduction in maintenance steroid doses. IS After validating the efficacy of this 'triple-drug cocktail' in kidney recipients, the first I-year survival of pancreas recipients was accomplished in June 1969. 19 The overwhelming mortality with these procedures restricted expansion of organ transplantation for another dozen years, Then, as the more potent cyclosporine and tacrolimus became available, the incidence of acute rejection as well as prednisonedependence declined, with an increase in survival of all kinds of organ grafts in three distinct leaps over a 4O-year period. Thus, the modern history of organ transplantation can be divided into successives eras: (I) azathioprine, (2) cyclosporine and (3) tacrolimus.
During the last decade, pancreas transplantation attained the level of a relatively reliable clinical service, and general agreement was finally reached about a standardized operation. With the definitive elucidation of the mechanisms of alloengraftment du ring the last 3 years, the stage has been set for further advances in what may be an era 4. Unlike eras 1-3, the impending era 4 may not depend on better immunosuppressants per se, but rather on better timing and more judicious dosing of agents that are already available.
The surgical operations
The azathioprine era After surgical technical problems were worked out in the canine model (summarized in ref. 20), Kelly and lillehei performed the first human operation at the University of Minnesota l9 on December 17, 1966 . Under azathioprine-prednisone immunosuppression, the whole cadaveric pancreas was transplanted to the left iliac fossa of a uraemic recipient after removing the duodenum and ligating the pancreatic duct. A kidney from the same donor was placed in the right iliac fossa. The recipient immediately became insulin-independent. but died at 2 months from a combination of rejection and sepsis. By 1973. Lillehei and Kelly had implanted 13 more whole human pancreas grafts. 21 Pancreatic secretions of the allografts were either exteriorized (cutaneous graft duodenostomy) or were directed via the graft duodenum into the host jejunum. using a Roux-en Y technique. The only recipient (the 6th) in this pioneer series of 14 cases to achieve long-lasting insulin independence died shortly after reaching the I-year milestone with a functioning pancreas after losing the kidney graft and returning to dialysis. The 13 other pancreas graft losses resulted from technical complications.
including vascular thrombosis. death with a functioning graft. and most commonly, lethal complications associated with exocrine pancreatic drainage.
With the premise that the Achilles heel of the operation was exocrine drainage, new strategies emerged to avoid entry into the host bowel for this purpose, to eliminate the donor duodenum from the graft, and to prevent or reduce the volume of the graft secretions. In 1973, Gliedman et al 22 reported excision of the graft duodenum and the adjacent pancreatic head with anastomosis of the segmental pancreatic duct to the recipient ureter. For the next dozen years distal pancreatic segments were used almost exclusively for transplantation.
The cyc/osporine era
With the more potent cyclosporine-based immunosuppression the reasons for abandonment of whole-pancreas transplantation were re-examined. The conclusion from this analysis was that transplantation of the whole pancreas ( Figure I ) was the best procedure, provided that the allograft exocrine secretions were drained into the host jejunum. In a crucial modification of the original Lillehei procedure. a 'bubble' of duodenum into which the ampulla of Vater emptied was retained with the allograft for anastomosis to the side of the host jejunum ( Figure 2 ). Two years later, the Iowa and Wisconsin teams advocated anastomosis of the bubble to the anterolateral wall of the host bladder rather than the bowel 23 . 24 ( Figure 3 ). With diversion of exocrine secretions into the bladder, serial measurement of urine amylase concentration became an accepted means of immune surveillance (i.e. a drop in amylase signalled rejection). However, digestion of the urethra by activated pancreatic enzymes, less serious but highly symptomatic damage to the lower urinary tract. uncorrectable metabolic acidosis..J::aused by the continuous loss of bicarbonate. and a myriad of other problems necessitating conversion to enteric drainage have diminished enthusiasm for bladder d rainage. 25 
The tauolimus era
The superior control of rejection with minimal dependence on prednisone using tacrolimus-based immunosuppression (era 3) has further eroded the arguments for exocrine diverSion to the bladder: I.e. the value of urinary amylase monltol-ing and of avoidance of an entenc anastomosis. Moreover. it has !:leen pOSSible in simplified tacr-oiimus-based ;-egimens to eliminate the perioperative induction therapy 'lVith .A,LC or [he cnonoclonai antibody. OKT3. that had become a standard component ot immunosuopression aunng era 2. 
Metabolic considerations

Portal versus systemic insulin release
The venous effluent from a pancreas allograft can be directed by vascular anastomosis into the systemic venous system or into the portal venous bed from where it passes through the liver under normal physiological conditions. Because insulin has important liver-supporting (hepatotrophic) properties 26 and also because the liver is the primary site of glucose homeostasis, an argument for portal drainage is readily apparent. In practice, however, this has not been an important issue, at least so far. Recipients of portally drained pancreas allografts usually have lower circulating insulin levels than those with the systemic drainage 27 but no clear difference in metabolic or clinical outcome. 28 Correction of metabolic deficits correction of ketoacidosis. The response to oral and intravenous glucose challenge and to secretagogues such as arginine are re-established.2 9 Because of improved glucagon and epinephrine responses, glucose-counter-regulation after hypoglycaemia is also restored. 30 . 31 This has a profound impact on the quality of life since after succp.ssful transplantation hypoglycaemic unawareness is unlikely to occur.32 The majority of subjects undergoing successful transplantation consider management of the immunosuppressive therapy preferable to insulin injections or other metabolic complications of the diseaseD
AmelioratIon of diabetes-assoclOted morbidity
Numerous studies have shown that a successful pancreas transplant can slow micro-'/a5cular complications. inciuding nephropathy. retinopathy and neuropathy [34] [35] [36] [37] DisapPOintingly. however. clear evidence has not emerged showing that pancreas transplantation can I-everse pre-existing lesions or completely prevent the progression \ \ Figure 3 . Pancreatico-duodenal allotransplantation with exocrine secretion drainage into the host bladder.
of new ones that are diabetes-related. This could be the result of factors that are independent of glycaemic control. Such questions about the full nature of the disease are being investigated in detail, including in long-term epidemiological studies of diabetic versus non-diabetic populations.
The worldwide experience
More than 15 000 pancreas transplants have been reported to the International Pancreas Transplantation Registry (IPTR).38 The actual number of cases is undoubtedly higher because not all centres report to this registry. Most of these complications can be traced to, or are aggravated by, the need for chronic immunosuppression. As described below. it may be pOSSible to rectify this problem at least partly.
Mechanisms of engraftment
In the different eras, the successful reversal of rejection was followed by a decline in anti donor graft reactivity that was reflected by a reduced need for immunosuppression, and in some cases by eventual or complete independence from maintenance therapy.47-49 Even when rejection is not clinically evident, the need for immunosuppression declines. The implication was that an allograft transplanted under non-speCific immunosuppression could induce variable degrees of antigen-specific non-reactivity (tolerance). 50 In each era, however, a policy drift ensued as soon as it was recognized that some of the rejections developing under monotherapy were intractable. The management change consisted oT instituting prophylactic high-dose steroid therapy from the time of transplantation to all recipients. As anti lymphoid and other agents were added pre-emptively in increasingly complex cocktails, the unchallenged tacit assumption was that the efficacy of the immunosuppressive regimens could be assessed primarily by t:he frequency with which acute rejection could be prevented. In addition. It was assumed that redUCing the incidence of early rejection to near zero would be "ewarded by 3 . commensurate decline in chronic rejection. Instead. chronic relection has become the greatest unresolved problem in the transplantation of all organs. With the possible exception of the liver.
Relinquishing the use of high-dose immunosuppression was difficult to defend. largely fJecause r:he mechanisms of alloengraftment were enigmatic. The first I'eal clue For organ engraftment, the two immune responses must be succeeded by z, significant degree of reciprocal clonal exhaustion-deletion ( Figure 5 ). The long-term maintenance of this acutely-achieved state of variable deletional tolerance depends on persistence of the donor leukocytes (micro-or macrochimerism) whose survival IS'aided by a second mechanism of immune indifference,54,55 Both mechanisms of antigen-specific non reactivity (clonal exhaustion-deletion and immune ignorance) are regulated by migration and localiz.ation of the only mobile antigen of the organ, namely, the donor leukocytes.S4.S5
Such organ-induced tolerance has been well documented in the absence of immunosuppression in a limited number of mouse, rat and pig models, most frequently involving, but not limited to, transplantation of the leukocyte rich liver (summarized in ref. 47) , In most models, however, and clinically, an umbrella of immunosuppression is required_ Otherwise, one immunocyte population destroys the other before the tolerogenic events can occur ( Figure 5 ). The usual outcome is organ rejection, but graft-versus-host disease (GVHD) may be the dominant pathophysiology in a number of experimental models and clinically. The outcomes of rejection or GVHD can be forestalled or permanently prevented in many animal models by treating the organ recipiem after transplantation with a short course of a wide variety of immunosuppressive drugs, or sometimes with a single dose.
Comparably conducive conditions for tolerance after human organ transplantation are predictably present only when tissues and organs are transplanted from HLA identical sibling donors. In addition, the short-term immunosuppl-ession used in experimental organ transplant models is contrary to the policy of heavy early immunosuppression (so-called 'induction therapy'), and to the commitment made at the outset to lifetime therapy. The early loss of allografts from immunological causes has been all but eliminated by intense immunosuppression, but not chronic rejection.
Because immune activation and subsequent clonal exhaustion-deletion is the seminal mechanism by which variable organ-induced non-reactivity is achievedsl-sS, the obvious question is whether conventional heavy immunosuppression early after transplantation erodes the window of opportunity for tolerogenesis that is opened with immune activation a few hours after graft revascularization reaches a zenith in 1-3 weeks, and is largely closed by I or 2 months ( Figure 5 ). We have addressed this issue recently, and have proposed two key therapeutic principles that must be observed if low-dose or no-dose immunosuppression is to be achieved in pancreas and other kinds of organ recipients.
The first treatment principle, exemplified by conventional bone marrow transplantation to cytoablated (e.g. irradiated) recipients, is that host pre-treatment facilitates alloengraftment. Near total chimerism with antigen-specific tolerance can be regularly established with clinical bone marrow transplantation to the cytoablated recipient, using minimal post-transplant immunosuppression. The reason is that, with host cytoablation before arrival of the mobile donor leukocytes, the donor-specific clonal expansion of the bone marrow recipient response is small enough to be acutely deleted by the infused donor haematopoietic cells before these donor cells are rejected. Although this has been accomplished clinically under the well standardized circumstances of conventional bone marrow transplantation. the widespread use of combined bone marrow-organ transplantation to cytoablated recipients has been precluded by the many parameters involved. of which the most restrictive is the need for a histocompatible donor for avoidance of GVHD.
The second key therapeutic principle is the avoidance of excessive and/or inappropriately timed (and therefore antitolerogenic) immunosuppression. The strong prophylactic immunosuppression conventionally used to inhibit the donor-specific T-cell response and avert rejection of the graft passenger leukocytes coincidentaily limits the extent of exhaustion-deletion and tolerogenesis, as has been demonstrated experimentally with prednisone, cyclosporine, tacrolimus and other agents.
Variable violations of both therapeutic principles are inevitable with compromise strategies between the radically different regimens of conventional bone marrow and organ transplantation. However. scrupulous adherence to the first principle of recipient pre-treatment, but using non-myelotoxic agents for conditioning (e.g. anti lymphoid antibody preparations). and observance of the second principle of minimal posttransplant immunosuppression, should improve clinical results. In addition, because the graft passenger leukocytes constitute, in essence, the eqUivalent of a bone man"ow infusion, it is rational to expect that the infusion of adjunct donor bone marrow cells will facilitate the clonal deletion induced by the comparable graft migratory leukocytes. In PJ.nc~·e3S and ISlet cell transplantation 467 the pastS" St, this desired effect of adjunct donor bone marrow probably has been sUDvened by over-immunosuppressions:
Either-without, 01-mon, likely with, adjunct donor bone man-ow infUSion, It may be possible to achieve drug-free tolerance in recipients of pancreas or othel-organs, using a clinical protOcol that was developed In 1966 after demonstrating that ALG had a more w!erogenlc effect when It was given before, rather than after-, kidney and liver tl-ansplantatlon in dogs,18 Under similar management in humans, but armed with modern drugs including powerful anti lymphoid antibody agents, a markedly reduced need for early and marntenance immunosuppression (Including nearly complete elimination of prednisone) has been reported from several centres. In Cambridge (England), Caine et al 58 have treated cadaver kidney recipients With a few perioperative doses of a humanized depleting anti-CD52 monoclonal antibody (T and B cell plus monocyte reactive), followed by low maintenance doses of cyclosporine alone. The results have been duplicated by Allen Kirk and associates in Bethesda by combining the antibody treatment with maintenance rapamycin. s9 Further suggesting that the therapy is not immunosuppressant-specific, but depends on the dose and timing of therapy, Kirk obtained similar results using a potent polyclonal ALG (ThymoglobulinR) and low-dose rapamycin S9 A potential era 4
The two therapeutic principles of recipient pre-treatment and minimal post-transplant immunosuppression were applied in Pittsburgh between July and November 200 I for four adult recipients of pancreas-only cadaveric allografts and for 10 kidney-pancreas recipients. Ten of the patients were also infused perioperatively with 5-9 x lOS unmodified bone marrow cells from the same donor. The patients were preconditioned with 3-5 mg(kg ThymoglobulinR IJnder the cover of I g intravenous methoprednisolone as prophylaxis against cytokine reactions, Treatment post-transplantation was with tacrolimus only with a trough target level of 10 ng/ml unless clinically significant rejection prompted the addition of a prednisone bolus(s), maintenance prednisone, or a short course of sirolimus.
All 14 of the pancreases and the 10 co-transplanted kidneys have functioned well with follow-ups that are now 2 weeks to 6 months. The absence, or easy control, of both early and late rejection in this consecutive cadaveric series, using minimum immunosuppression relative to all previous experience in pancreas transplantation, has been remarkable. The value of this approach has been supported by similar results in a contemporaneous series of 31 recipients of cadaveric kidneys who had even less need for immunosuppression other than tacrolimus monotherapy, An attempt at complete weaning of immunosuppression is planned for patients under monotherapy whose allograft biopsy(ies) at 100 days shows no evidence of destructive immunity. Patients who have donor leukocyte chimerism demonstrable by flow cytometry in blood samples (i.e. macrochimerism) will be considered particularly good candidates for weaning.
PANCREATIC ISLET TRANSPLANTATION
The concept of removing islets from the whole pancreas for separate engraftment was advanced as early as 1902.60 Eighty years later it was demonstrated in animal models 61 . 62 and clinically63 that a high rate of success with islet transplantation can be expected in the absence of an immune barrier (i.e. using autografts). In most of the autotransplant trials, the pancreas was removed surgically (e.g. for pancreatitis), purified islets were extracted from the specimen, and these were infused Into the patient's liver via the portal vein. Efforts to duplicate such results with allograft islets were not rewarded with success in experimental animals until the 19805, or in humans until 1990.
In the first successful transplantation of islet allografts, five patients in Pittsburgh underwent upper abdominal exenteration (which included removal of the liver, stomach and whole pancreas), followed by liver transplantation. 64 The patients were rendered free of exogenous insulin for up to 5 years by intraportal infusion of pancreatic islet allografts that had been prepared from the pancreas of the liver donor. However, when the same investigators attempted islet transplantation in nearly three dozen patients with juvenile diabetes, complete long-term insulin independence was not achieved in any case.
Subsequently, several groups have documented metabolic normalization after the transplantation of islet allografts in patients with type I diabetes. Some 237 such attempts were reported to the International Islet Transplant Registry (IITR) between 1990 and 1999, with insulin independence at I year in about 10%.65 Most recently, Shapiro et al reported successful metabolic correction in seven consecutive type I recipients of islets, most commonly requiring islets from more than one donor.66 Immunosuppression was provided initially with an anti-interleukin-2 receptor antagonist (daclizumab). Continuous post-transplant treatment was with a steroid-free drug combination based on tacrolimus. Efforts to duplicate these results in several European and American centres have confirmed the feasibility of the islet procedure, but not its reliability. Consequently, in addition to pursuing these trials in multiple centres, efforts are being made to determine the precise conditions that lead to more consistently successfu I engraftment:
I. Isolation of islets. This first step involves enzymatic digestion of the pancreas 67 , achieved by intraductal injection of a solution containing collagenase or a recently improved blend of enzymes (Liberase R ). The digestion is combined with mechanical disruption in a semi-automated digestion chamber developed by Ricordi et al 68 After separation of the islets and discard of the acinar cells, islet clusters remain of variable size, each ranging from 50 to 500 ~lm in diameter. The implantable pellet of islets has a compacted volume of only 1-3 ml. It has been estimated that approximately 50% of the original islet mass has already been lost by this stage. Ways of obtaining a better yield are being sought.
CharacterizatIOn of the islets.
Many studies have focused on the effect of different culture media and supplements that would allow preservation of islet mass. In addition to making islet transplantation an elective procedure, this would allow time to assess in vitro the function and other qualities of the potential grafts. 69 .70 Cryopreservation also has been shown to be feasible ' I. 81 -86 The most common implantation site in clinical trials has been within the liver via intra-portal inlectionlO.87 Whethel" the liver is the optimal place fOI" engraftment has not been proved.
6. Glucose counter-regulation. In contrast to whole-organ transplantation, the glucagon response to hypoglycaemla and other counter-regulatory mechanisms in recipients of well-functioning islet grafts appears to be impaired 88 . 89 ; this may be related to the implantation site.
Immunosuppression and alloengraftment
As described under Pancreas Transplantation, the engraftment of all whole organs, including the pancreas, begins with acute chimerism-dependent induction of some level of deletional tolerance. The subsequent maintenance of the clonal exhaustion requires the persistence of small numbers of donor leukocytes (microchimerism) whose survival is facilitated by migration of donor leukocytes to 'protected' nonlymphoid areas where the donor cells may be 'ignored' by the host immune system until they leak back to host lymphOid organs and perpetuate clonal exhaustiondeletion. 54 . 55 In such cases, immune ignorance of the cells in non-lymphoid locations is a secondary (or collaborative) mechanism for maintenance of clonal deletion, as described in detail elsewhere s4 . 55 In contrast to whole organs, small bits of endocrine tissue that fail to reach organized lymphoid collections may be unrecognized by the host immune system. In an early example of such immune ignorance, Stone, Owings and Gey90 reported in 1934 that parathyroid tissue, which had been cultured for 2 weeks and transplanted into loose areolar subcutaneous tissue, functioned for prolonged periods in canine and human recipients. Long regarded as not credible, the findings of these authors are explained in retrospect by two features of the procedure. The first was the choice of a subcutaneous implantation site, which. like other privileged sites (e.g. hamster cheek pouch. brain), has limited lymphatic drainage. The second feature of this procedure became apparent with Lafferty'S demonstration that tissue culture comparable to that used four decades earlier in the parathyrOid experiments of Stone et al depletes endocrine tissue of passenger leukocytes that are capable of migrating to host lymphoid organs. 91 In principle. the use of highly bio-compatible materials used to encapsulate islet cells is an attempt to achieve immune indifference with a mechanical barrier. 92 . 93 Howev~r, because islets have insufficient donor leukocyte antigen to induce deletion. it is possible that the islet engraftment may be achieved primarily by immune ignorance without encapsulation, resembling the 'Stone-Lafferty' graft. This could occur if the small numbers of mobile donor leukocytes contained in a bolus of islets made their way to host lymphoid organs and were 'all' destroyed. allowing the leukocyte-depleted islets in distant non-lymphoid locations to be ignored by the host for long periods, or permanently. From practical experience. and particularly that of the Edmonton group, it would appear that the immunosuppression most conducive for this chain of events may be the same as that fo~ whole-organ transplantation: i.e. recipient pre-treatment and minimal steroid-free post-transplant therapy.
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XENOTRANSPLANTATION
The prospect of providing either a whole pancreas or islets for the large number of diabetic patients that could benefit from transplantation is limited by the shortage of donors. At present more than one islet donor is required to accomplish glucose normalization and long-term maintenance may require further cell infusions. The solution may be the use of animal donors. 94 Because human and porcine insulin have high amino acid sequence homology and have other metabolic similarities, including glucose homeostasis and regulation of insulin secretion, the pig may be a suitable source for islet cells or for the whole pancreas. A pilot study performed in Sweden has shown that fetal porcine islets can be implanted in humans, but these xenografts have had short functional activity because of rejection by predominantly innate immune mechan isms. 95 The best characterized target antigen on the cells of lower mammals (e.g. pig) is the surface carbohydrate epitope galactose rx(I-3)galactose, which is similar to substances found on numerous bacteria, protozoa and viruses. Efforts to create transgenic pigs that have this and other suspect genes replaced or knocked-out are underway.96,97 Combined with cloning technology, they may allow the creation of 'humanized' animals for clinical use.
Practice points
• besides insulin. a definitive treatment for type I diabetes can be achieved only with whole-pancreas or islet-cell transplantation • long-term normalization of glycaemia is achieved by whole-pancreas transplants.
limited by technical complications of the extensive surgery • islet transplantation is non-invasive; it is limited in its use by the need for multiple donors • immunosuppressive regimens are necessary in both types of transplant to limit the negative effects of recurrent autoimmunity and allorejection • immunosuppressants allow successful transplants in adults, but not in children
Research agenda
• tolerization protocols need to be implemented. Immunological preconditioning by anti-T cell antibodies (e.g. Tymoglobulin) and donor bone marrow administration could represent a possible approach for the induction of haematological chimerism of the recipient • alternative sources of insulin-producing ~ cells can be found among the stem cells present in the individual's tissues (e.g. endocrine pancreas, bone marrow, liver). These precursors should be immunologically recognized and then induced to proliferate and differentiate I • the limit in organ availability can also be overcome by generating animal donors I (e.g. pigs) with tissues immunologically more acceptable by the human recipient. I allowing xenotransplantation
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